CIK 0001674416
- Large accelerated filer
CRISPR Therapeutics AG
Sign in to watch- Ticker
- CRSP
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- Switzerland
- Entity type
- Operating
- EIN
- 473173478
- Phone
- +1 617-315-4600
- Business address
- BAARERSTRASSE 14, ZUG, Switzerland
- Former names
- CRISPR Therapeutics AG
- 4 Open-market sale 10% owner sold 101,994 shares at an average $50.68 ($5,168,901)
- 4 Open-market sale Director sold 101,994 shares at an average $50.68 ($5,168,901)
- 4 Open-market sale Director sold 101,994 shares at an average $50.68 ($5,168,901)
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Open-market buy 10% owner bought 527,472 shares at $22.75 ($11,999,988)
- 4 Open-market sale Chief Legal Officer sold 66,000 shares at an average $28.03 ($1,850,255)
- 4 Open-market buy Director bought 65,934 shares at $22.75 ($1,499,999)
- 4 Open-market sale Director sold 92,337 shares at $26.96 ($2,489,406)
- 4 Open-market sale Chief Legal Officer sold 38,000 shares at an average $21.64 ($822,500)
- 4 Open-market sale Director sold 37,754 shares at $26.76 ($1,010,123)
- 4 Open-market sale Chief Legal Officer sold 31,000 shares at an average $22.72 ($704,280)
- 4 Open-market sale Chief Legal Officer sold 15,000 shares at $20.55 ($308,250)
- 4 Open-market sale Director sold 26,016 shares at $20.30 ($528,237)
- 4 Open-market sale Director sold 3,059 shares at $20.29 ($62,070)
- 4 Exercise or conversion Chief Executive Officer acquired 15,000 shares (option exercise)
Page 20 of 26 · 502 filings